Welcome to our dedicated page for Astera Labs SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Astera Labs's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Astera Labs's regulatory disclosures and financial reporting.
Astera Labs, Inc. General Counsel and Secretary Philip Mazzara acquired additional company stock through an employee purchase program. On May 14, 2026, he received 131 shares of common stock at $120.1815 per share under the 2024 Employee Stock Purchase Plan, bringing his direct holdings to 118,215 shares. The filing notes these plan purchases were exempt under Rule 16b-3(d) and Rule 16b-3(c).
ALAB submitted a Form 144 disclosure listing proposed resale of common stock and several previously issued restricted stock grants. The filing shows two reported open-market dispositions by Philip Mazzara of 10,000 shares each on 03/02/2026 and 04/01/2026, with proceeds of $1,174,740.60 and $1,077,662.85, respectively. The excerpt also lists restricted stock issuances dated 08/15/2024, 11/15/2023, 02/15/2024, 08/15/2023, and 05/15/2024 with individual share counts shown.
ALAB notice under Form 144 reports proposed sales tied to restricted stock vesting and multiple dispositions by Michael Truett. The filing lists vesting entries of 29,937, 12,020, 7,014, and 694 shares with vesting dates in 2024 and 2025. The filing also discloses sales by Michael Truett on 02/17/2026 of 4,250, 3,556, 2,281, 1,161, and 753 shares, each with accompanying dollar amounts reported.
Astera Labs, Inc. director and President/COO Gajendra Sanjay reported insider sales executed through estate-planning trusts. On May 7, 2026, trusts identified as "Trust 2" and "Trust 3" sold an aggregate of 49,361 shares of Common Stock in a series of open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025.
The reported weighted average sale prices span ranges disclosed in multiple footnotes, including transactions within bands such as $192.4400 to $193.4300 and up to higher ranges reflected in individual line items. Following these transactions, Sanjay continues to hold 1,531,301 shares directly, while the trusts still hold over 650,000 shares each. The filing states that the shares in Trust 2 and Trust 3 are owned directly by estate planning trusts, and Sanjay disclaims beneficial ownership except to the extent of any pecuniary interest.
Astera Labs, Inc. estate planning trusts reported sizeable planned share sales. On May 7, 2026, trusts associated with President and COO Gajendra Sanjay sold a total of 230,639 shares of Astera Labs common stock in a series of open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025. Individual blocks were sold at prices including $198.8237 and $213.49 per share. After these sales, one estate planning trust (Trust 1) reported holding 5,859,488 shares, while a second trust (Trust 2) reported holding 694,055 shares. The filing states that Sanjay disclaims beneficial ownership of these trust-held securities except to the extent of any pecuniary interest.
Astera Labs, Inc.’s CEO Mohan Jitendra reported multiple open-market sales of Common Stock on May 7, 2026, totaling 139,951 shares. The transactions were executed by a living trust associated with him under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025.
Sale prices ranged around $199–$206 per share, reported as weighted averages across several trades. After these sales, the living trust still held 3,929,183 shares of Astera Labs Common Stock, while Jitendra also held additional shares directly and through several estate planning trusts.
Astera Labs director Stefan A. Dyckerhoff reported open-market sales totaling 12,499 shares of Common Stock on May 7, 2026. The shares were sold at weighted-average prices of $201.102 and $199.00 per share under a Rule 10b5-1 trading plan adopted on December 1, 2025.
After these sales, Dyckerhoff holds 65,361 shares directly and additional indirect positions, including 332,160 shares held by a trust and 6,278 shares held by a limited partnership, where he disclaims beneficial ownership except for his pecuniary interest.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting an affiliate's proposed sale of 40,000 shares of Common Stock of ALAB. The filing lists an aggregate amount of $8,556,400.00 and reports 171,407,939 shares outstanding as of 05/07/2026. The shares were acquired on 11/21/2017 via a Private Acquisition from Issuer or an Affiliate.
Morgan Stanley Smith Barney LLC reported an intent to sell 40,000 shares of Common stock of ALAB via a Form 144. The filing shows an aggregate amount of $8,556,400.00 and lists 171,407,939 shares outstanding as of 05/07/2026. The shares were acquired 11/21/2017 in a Private Acquisition from Issuer or an Affiliate.
Morgan Stanley Smith Barney LLC filed a Form 144 notice reporting proposed sale of 200,000 common shares of ALAB. The securities were originally acquired 11/21/2017 in a private acquisition from the issuer or an affiliate. The filing shows a NASDAQ listing and a filing date of 05/07/2026.